HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel

Author: Di Leo A.  

Publisher: Springer Publishing Company

ISSN: 0167-6806

Source: Breast Cancer Research and Treatment, Vol.86, Iss.3, 2004-08, pp. : 197-206

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content